Nautilus Biotechnology (NASDAQ:NAUT) Shares Down 5.9% – Here’s What Happened

Nautilus Biotechnology, Inc. (NASDAQ:NAUT) was down 5.9% during mid-day trading on Tuesday . The company traded as low as $1.57 and last traded at $1.60. Approximately 119,589 shares changed hands during mid-day trading, an increase of 4% from the average daily volume of 114,703 shares. The stock had previously closed at $1.70.

Wall Street Analysts Forecast Growth

Separately, The Goldman Sachs Group downgraded shares of Nautilus Biotechnology from a “neutral” rating to a “sell” rating and dropped their target price for the stock from $2.25 to $1.75 in a report on Thursday, December 5th.

Nautilus Biotechnology Trading Down 5.9 %

The firm has a market capitalization of $200.90 million, a P/E ratio of -2.86 and a beta of 1.21. The firm has a 50 day moving average price of $1.84 and a 200-day moving average price of $2.33.

Hedge Funds Weigh In On Nautilus Biotechnology

A number of large investors have recently made changes to their positions in the company. Barclays PLC lifted its stake in Nautilus Biotechnology by 79.6% in the third quarter. Barclays PLC now owns 106,174 shares of the company’s stock worth $303,000 after purchasing an additional 47,059 shares during the last quarter. The Manufacturers Life Insurance Company purchased a new stake in shares of Nautilus Biotechnology in the third quarter worth approximately $67,000. MetLife Investment Management LLC purchased a new stake in shares of Nautilus Biotechnology in the third quarter worth approximately $87,000. China Universal Asset Management Co. Ltd. lifted its stake in shares of Nautilus Biotechnology by 63.9% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 24,121 shares of the company’s stock worth $69,000 after acquiring an additional 9,404 shares during the last quarter. Finally, SG Americas Securities LLC purchased a new position in Nautilus Biotechnology during the 3rd quarter valued at $50,000. 50.71% of the stock is owned by hedge funds and other institutional investors.

About Nautilus Biotechnology

Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.